Application of human PNO1 gene in lung cancer and related product

A gene, lung cancer technology, applied in the field of biomedical research

Inactive Publication Date: 2020-07-07
TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no relevant report on the use of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human PNO1 gene in lung cancer and related product
  • Application of human PNO1 gene in lung cancer and related product
  • Application of human PNO1 gene in lung cancer and related product

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0113] Example 1. Detection of PNO1 expression level in tumor tissues of patients with lung cancer by immunohistochemical method

[0114] Immunohistochemistry was applied to paraffin-embedded LADC samples (from the Department of Pathology, Tianjin Medical University Cancer Hospital) (the primary antibody was Anti-PNO1 Antibody, brand LifeSpan, catalog number LS-C179090; the secondary antibody was a rabbit two-step kit, Brand Zhongshan Jinqiao, Cat. No. PV-6001) to detect the expression level of PNO1 in tumor cells, establish the immunohistochemical score, and further analyze the relationship between the expression level of PNO1 and the survival prognosis and clinicopathological indicators. Immunohistochemical scoring rules: The staining intensity of immunohistochemistry is divided into areas between 0 and 3 (0 means no immune response, 1 means weak immune response, 2 means moderately strong immune response, 3 means strong immune response) The immunohistochemical staining perce...

Embodiment 2

[0116] Example 2. Western Blotting Detection of PNO1 Expression Levels in Tumor Tissues and Paracancerous Tissues of Patients with Lung Cancer

[0117] The surgically resected fresh lung cancer samples (tumor tissues and paracancerous tissues of patients with lung adenocarcinoma, from the Cancer Hospital of Tianjin Medical University) were frozen in liquid nitrogen, and tissue proteins were extracted with a tissue protein extractor. Protein extraction Cells were lysed with RIPA lysate, the whole protein was extracted, and the protein concentration was determined by BCA method. Each histone was separated by 10% SDS-PAGE gel electrophoresis. After separation, the protein was transferred to a PVDF membrane and blocked with 5% skimmed milk powder at room temperature for 1 hour. Add the primary antibody (Anti-PNO1 Antibody, brand LifeSpan, product number LS-C179090) and incubate overnight at 4°C with a shaker. After washing the membrane, add the corresponding secondary antibody (G...

Embodiment 3

[0119] Example 3. RT-PCR detection of PNO1 mRNA levels in tumor tissues and paracancerous tissues of patients with lung cancer

[0120] The surgically resected fresh lung cancer samples (tumor tissues and paracancerous tissues from patients with lung adenocarcinoma, from the Cancer Hospital of Tianjin Medical University) were frozen in liquid nitrogen, ground with a mortar and mortar for mRNA extraction, and then TRIzol reagent (Invitrogen ) to extract total RNA from lung cancer tissue, and perform reverse transcription, the obtained cDNA was used Premix Ex TaqTM (PerfectReal Time) reagent (TaKaRa) carried out real-time quantitative PCR according to its instructions, upstream primer 5'-GGCTCCTGAGTGGGAAAGAA-3' (SEQ ID NO:7) and downstream primer 5'-CAAGTGCATCCTCACCTGA-3' (SEQ ID NO:8 ). The differences in the mRNA level of PNO1 in cancer and its corresponding paracancerous tissues were detected.

[0121] The result is as figure 2 , B shows that PNO1 has differential expres...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to RNA-binding protein PNO1 capable of being used as a lung cancer diagnosis target and treatment target, and particularly discloses overexpression of the RNA-binding protein PNO1 in lung cancer cells. Overexpression of the RNA-binding protein PNO1 in the lung cancer cells can promote proliferation of the lung cancer cells, and is related to short prognosis survival time of lung cancer patients. By reducing expression of the PNO1, growth and metastasis of the lung cancer cells are inhibited, and apoptosis of the lung cancer cells is increased, so that inhibition of expression of the PNO1 represents a novel strategy for treating lung cancer.

Description

technical field [0001] The invention belongs to the field of biomedicine research, and specifically relates to the use of human PNO1 gene and related products. Background technique [0002] Lung cancer is one of the malignant tumors with the fastest-growing morbidity and mortality and the greatest threat to the health and life of the population. Lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for 85% of lung cancer cases, and can be further divided into three types by histopathological heterogeneity, including adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large cell carcinoma. Adenocarcinoma (LADC) accounts for more than 50% of cases in NSCLC. Due to the heterogeneity of lung cancer, there is no effective individualized diagnosis and treatment plan at present, and it is urgent to develop new drug targets and biomarkers for prognosis prediction that can be used in the treatment of lung cancer. [0003] St...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886C12N15/11G01N33/577G01N33/574
CPCC12Q1/6886G01N33/577G01N33/57423G01N2500/10
Inventor 郭华陈鹏刘志勇陈丽维罗艺陈璐刘东明林丽张翠翠
Owner TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products